Despite strong correlations linking whole-grain consumption to reductions in heart disease, the physiological mechanisms involved remain ambiguous. We assessed whether Salba (Salvia Hispanica L.) whole grain reduces postprandial glycemia in healthy subjects, as a possible explanation for its cardioprotective effects observed in individuals with diabetes. The study used acute, randomized, double-blind, controlled design in which 11 healthy individuals (6 males and 5 females; body mass index 22.3±2.8 kg/m2) received 0, 7, 15 or 24 g of Salba baked into white bread. Capillary samples and appetite ratings were collected over 2 h after consumption. A dose-response reduction in postprandial glycemia (P=0.002, r2=0.203) was observed with all three doses of Salba, significantly decreasing incremental areas under the curve (iAUCs) and time point-specific blood glucose (P<0.05). Appetite ratings were decreased at 60 min after high, 90 min after high and intermediate and at 120 min after all treatments (P<0.05). Decrease in postprandial glycemia provides a potential explanation for improvements in blood pressure, coagulation and inflammatory markers previously observed after 12-week Salba supplementation in type II diabetes.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Blundell JE, Rogers PJ (1991). Hunger, hedonics, and the control of satiation and satiety. In: Friedman MI, Tordoff MG, Kare MR (eds). Chemical Senses, Vol IV. Appetite and Nutrition. Marcel Dekker: New York. pp 127–148.
Brouns F, Bjorck I, Frayn KN, Gibbs AL, Lang V, Slama G et al. (2005). Glycaemic index methodology. Nutr Res Rev 18, 145–171.
Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E et al. (1996). Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 39, 469–473.
Chiasson JL (2006). Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 12 (Suppl 1), 25–30.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003). Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290, 486–494.
Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999). The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95 783 individuals followed for 12.4 years. Diabetes Care 22, 233–240.
Gentilcore D, Bryant B, Wishart JM, Morris HA, Horowitz M, Jones KL (2005). Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med 118, 1289.
Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP et al. (2006). Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295, 1681–1687.
O’Keefe JH, Bell DS (2007). Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 100, 899–904.
O’Keefe JH, Gheewala NM, O’Keefe JO (2008). Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 51, 249–255.
Read N, French S, Cunningham K (1994). The role of the gut in regulating food intake in man. Nutr Rev 52, 1–10.
Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N (2006). Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 91, 837–842.
Vuksan V, Whitham D, Sievenpiper JL, Jenkins AL, Rogovik AL, Bazinet RP et al. (2007). Supplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial. Diabetes Care 30, 2804–2810.
Wolever TM, Jenkins DJ, Jenkins AL, Josse RG (1991). The glycemic index: methodology and clinical implications. Am J Clin Nutr 54, 846–854.
Salba Smart Natural Products, Denver, CO, USA, provided Salba grain. The results were presented as an abstract at Experimental Biology 2008 (The FASEB Journal. 2008;22:305.6), supported by an unrestricted travel grant received from Salba Corporation S.A, Buenos Aires, Argentina.
About this article
Cite this article
Vuksan, V., Jenkins, A., Dias, A. et al. Reduction in postprandial glucose excursion and prolongation of satiety: possible explanation of the long-term effects of whole grain Salba (Salvia Hispanica L.). Eur J Clin Nutr 64, 436–438 (2010). https://doi.org/10.1038/ejcn.2009.159
Co-administration of viscous fiber, Salba-chia and ginseng on glycemic management in type 2 diabetes: a double-blind randomized controlled trial
European Journal of Nutrition (2021)
Acute effect of Clitoria ternatea flower beverage on glycemic response and antioxidant capacity in healthy subjects: a randomized crossover trial
BMC Complementary and Alternative Medicine (2018)
Comparison of flax (Linum usitatissimum) and Salba-chia (Salvia hispanica L.) seeds on postprandial glycemia and satiety in healthy individuals: a randomized, controlled, crossover study
European Journal of Clinical Nutrition (2017)
Phytochemistry Reviews (2017)
Journal of Food Science and Technology (2016)